肝移植后移植物评估风险评分模型评价早期移植物功能
该回顾性单中心研究基于2002至2015年2008例成人首次肝移植受者数据,开发了L-GrAFT风险评分以个体化预测移植后3个月移植物失败。L-GrAFT模型C统计量为0.85,显著优于现有EAD定义(0.68,P<.001)和MEAF评分(0.70,P<.001)。
要点
- L-GrAFT评分可高精度个体化预测肝移植后3个月移植物失败风险。
- L-GrAFT区分度显著优于现有EAD定义和MEAF评分。
- 高L-GrAFT风险患者供受体因素更差,冷缺血时间更长。
核心结论
- L-GrAFT风险评分能高度准确个体化估计肝移植后3个月移植物失败风险。
- L-GrAFT评分比现有EAD定义和MEAF评分更准确。
- 多中心验证后L-GrAFT可能用于评估再移植需求、标准化早期移植物功能分级及作为临床终点。
研究设计与样本
- 回顾性单中心分析,使用UCLA Dumont移植中心2002年2月1日至2015年6月30日移植数据库。
- 纳入所有成人首次肝移植且具备移植后10天实验室变量数据的患者。
- 共2021例首次肝移植患者,2008例(99.4%)纳入分析;受者中位年龄56岁(IQR 49-62),1294例(64.4%)为男性。
主要发现
- 总体生存率和无移植物失败生存率:1年分别为83%和81%,3年分别为74%和71%,5年分别为69%和65%。
- 3个月移植物失败或死亡发生率为11.1%(222例)。
- 与3个月无移植物失败生存相关的多因素包括移植后AST、INR、胆红素和血小板计数,用于计算L-GrAFT评分。
- L-GrAFT模型C统计量为0.85,显著优于EAD定义(C统计量0.68;P<.001)和MEAF评分(C统计量0.70;P<.001)。
- L-GrAFT评分最高10%患者相比低风险患者:MELD中位数34(IQR 26-40) vs 31(25-38),P=.005;移植前住院56.8% vs 44.8%,P=.003;肾脏替代治疗42.9% vs 30.5%,P<.001;机械通气35.8% vs 18.1%,P<.001;血管活性药物22.9% vs 11.0%,P<.001;冷缺血时间中位数436分钟(IQR 311-539) vs 401分钟(302-506),P=.04;术中红细胞输注中位数17单位(IQR 10-26) vs 10单位(6-17),P<.001;供者年龄中位数47岁(IQR 28-56) vs 41岁(25-52),P<.001。
关键数值与推荐
- 现有EAD定义:术后第7天胆红素≥10 mg/dL,或术后第7天INR≥1.6,或术后7天内AST或ALT>2000 U/L。
- L-GrAFT评分基于移植后AST、INR、胆红素和血小板计数计算。
- 主要结局为3个月无移植物失败生存。
临床怎么用
- L-GrAFT评分可用于肝移植后个体化风险分层,识别3个月移植物失败高风险患者。
- 高L-GrAFT评分患者可能需要更密切监测和评估再移植需求。
- L-GrAFT评分可作为临床研究中评估早期移植物功能的准确终点。
局限性
- 回顾性单中心分析,需多中心验证后方可推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early allograft dysfunction (EAD) following a liver transplant (LT) unequivocally portends adverse graft and patient outcomes, but a widely accepted classification or grading system is lacking. OBJECTIVE: To develop a model for individualized risk estimation of graft failure after LT and then compare the model's prognostic performance with the existing binary EAD definition (bilirubin level of ≥10 mg/dL on postoperative day 7, international normalized ratio of ≥1.6 on postoperative day 7, or aspartate aminotransferase or alanine aminotransferase level of >2000 U/L within the first 7 days) and the Model for Early Allograft Function (MEAF) score. DESIGN, SETTING, AND PARTICIPANTS: This retrospective single-center analysis used a transplant database to identify all adult patients who underwent a primary LT and had data on 10 days of post-LT laboratory variables at the Dumont-UCLA Transplant Center of the David Geffen School of Medicine at UCLA between February 1, 2002, and June 30, 2015. Data collection took place from January 4, 2016, to June 30, 2016. Data analysis was conducted from July 1, 2016, to August 30, 2017. MAIN OUTCOMES AND MEASURES: Three-month graft failure-free survival. RESULTS: Of 2021 patients who underwent primary LT over the study period, 2008 (99.4%) had available perioperative data and were included in the analysis. The median (interquartile range [IQR]) age of recipients was 56 (49-62) years, and 1294 recipients (64.4%) were men. Overall survival and graft-failure-free survival rates were 83% and 81% at year 1, 74% and 71% at year 3, and 69% and 65% at year 5, with an 11.1% (222 recipients) incidence of 3-month graft failure or death. Multivariate factors associated with 3-month graft failure-free survival included post-LT aspartate aminotransferase level, international normalized ratio, bilirubin level, and platelet count, measures of which were used to calculate the Liver Graft Assessment Following Transplantation (L-GrAFT) risk score. The L-GrAFT model had an excellent C statistic of 0.85, with a significantly superior discrimination of 3-month graft failure-free survival compared with the existing EAD definition (C statistic, 0.68; P < .001) and the MEAF score (C statistic, 0.70; P < .001). Compared with patients with lower L-GrAFT risk, LT recipients in the highest 10th percentile of L-GrAFT scores had higher Model for End-Stage Liver Disease scores (median [IQR], 34 [26-40] vs 31 [25-38]; P = .005); greater need for pretransplant hospitalization (56.8% vs 44.8%; P = .003), renal replacement therapy (42.9% vs 30.5%; P < .001), mechanical ventilation (35.8% vs 18.1%; P < .001), and vasopressors (22.9% vs 11.0%; P < .001); longer cold ischemia times (median [IQR], 436 [311-539] vs 401 [302-506] minutes; P = .04); greater intraoperative blood transfusions (median [IQR], 17 [10-26] vs 10 [6-17] units of packed red blood cells; P < .001); and older donors (median [IQR] age, 47 [28-56] vs 41 [25-52] years; P < .001). CONCLUSIONS AND RELEVANCE: The L-GrAFT risk score allows a highly accurate, individualized risk estimation of 3-month graft failure following LT that is more accurate than existing EAD and MEAF scores. Multicenter validation may allow for the adoption of the L-GrAFT as a tool for evaluating the need for a retransplant, for establishing standardized grading of early allograft function across transplant centers, and as a highly accurate clinical end point in translational studies aiming to mitigate ischemia or reperfusion injury by modulating donor quality and recipient factors.
引用
- Agopian VG, Harlander-Locke MP, Markovic D, et al. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model. JAMA Surg. 2018. PMID: 29261831. doi:10.1001/jamasurg.2017.5040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。